Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation

Abstract Although ruxolitinib contributes to immunomodulation and can lead to severe infections, it seems a feasible treatment strategy for patients with polycythemia vera and myelofibrosis after liver transplantation.

Bibliographic Details
Published in:Clinical Case Reports
Main Authors: Leona Dold, Philipp Lutz, Annkristin Heine, Tobias J. Weismüller, Christian P. Strassburg, Ulrich Spengler
Format: Article
Language:English
Published: Wiley 2021-09-01
Subjects:
liver transplantation
myelofibrosis
polycythemia vera
ruxolitinib
Online Access:https://doi.org/10.1002/ccr3.4782

Internet

https://doi.org/10.1002/ccr3.4782

Similar Items